Home / Guides / Zepbound alternatives
Too pricey or not covered? Start here.
Zepbound alternatives: what to do when it costs too much or isn’t covered
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
NexLife publishes this guide and is one of the programs in it. Every program, ours included, faces the same tests, and every price links to its source.
If Zepbound costs too much, your options as of November 1, 2026 are LillyDirect’s self-pay prices ($299–$449), Wegovy pens ($349) and
$139/mo on 12 months, every dosePrice Match Guarantee†
- Wegovy pens: $349 a month; $199 for a new patient’s first two fills through December 31, 2026
GLP-1 pills: Foundayo or the Wegovy pill, $149 to $299- Medicare Part D: $50 a month through the Bridge, if eligible
$139/mo on a 12-month plan, all-inclusive, same price at every dose
Or $169/mo month to month
Brand-name Zepbound: $299 to $449 a month at LillyDirect, by dose; $449 needs a refill within 45 days, or it’s $499 to $699
About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication
See all 4 plans and what a year costs
| Plan | Per month | 12 months at this rate |
|---|---|---|
| 12-month Lowest monthly price | $139 | $1,668 |
| 6-month | $149 | $1,788 |
| 3-month | $159 | $1,908 |
| Month to month | $169 | $2,028 |
Month to month costs $360 more over 12 months than the 12-month plan. Plans renew until you cancel. Longer plans bill the way you choose at checkout.
Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works
4.8 out of 5 on Trustpilot, 407 reviewsLegitScript-certified
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.
- Licensed U.S. providers
- LegitScript certified
- Free expedited shipping
- HSA, FSA, Affirm, Klarna, Afterpay
- 24/7 support, real people
- Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)
Compounded tirzepatide isn’t FDA-approved, isn’t a generic and isn’t Zepbound. A licensed provider prescribes it only when it offers a significant difference for you.
What are your options?
| Question | Answer |
|---|---|
| Can you stay on Zepbound for less? | Yes, self-pay at LillyDirect: $299 at 2.5 mg, $399 at 5 mg; $449 from 7.5 mg with a refill within 45 days, or $499 to $699. |
| Is Wegovy cheaper? | At most doses: Wegovy pens are $349 a month self-pay, or $199 for a new patient’s first two fills through December 31, 2026. |
| Is there a pill? | Yes: Foundayo or the Wegovy pill, $149 to $299 a month, by dose. |
| On Medicare Part D? | The |
| Have type 2 diabetes? | Ask about Mounjaro: $499 a month at LillyDirect. It’s approved for type 2 diabetes, not weight loss. |
| What about compounded tirzepatide? | $139 to $399 month to month in our price index (median $237, checked November 1, 2026). It isn’t Zepbound or FDA-approved. At NexLife: $139 a month on the 12-month plan. |
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Zepbound alternatives: Wegovy pens at $349 a month,
GLP-1 pills at $149 to $299, or compounded tirzepatide (checked November 1, 2026). - Staying on Zepbound? LillyDirect charges $299 to $449 by dose; $449 needs a refill within 45 days, or it’s $499 to $699.
- Coverage can come back: CVS Caremark’s template formularies added Zepbound back on October 1, 2026; plans can customize.
- Medicare Part D: the
GLP-1 Bridge covers the Zepbound KwikPen, Wegovy and Foundayo for $50 a month if you qualify. - Watch December 31, 2026: Lilly’s savings cards, Wegovy’s $199 starter fills and Foundayo’s reduced prices end.
- At NexLife, compounded tirzepatide is $139 a month on the 12-month plan; it isn’t Zepbound or FDA-approved.
At a glance
How do the Zepbound alternatives compare?
Here’s each option side by side. All are FDA-approved except compounded tirzepatide, and every price is what you’d pay yourself.
| Option | Who makes it | FDA-approved for | How you take it | Dose range | Self-pay, a month | Coverage and Medicare |
|---|---|---|---|---|---|---|
| Zepboundtirzepatide, vial or KwikPen | Eli Lilly | Weight loss and keeping it off; moderate to severe sleep apnea with obesity, in adults | A weekly shot | 2.5 to 15 mg | $299 to $449 at LillyDirect; $449 needs a refill within 45 days, or it’s $499 to $699 | Bridge: $50 for the KwikPen if you qualify. Lilly’s $25 savings card ends December 31, 2026 |
| Mounjarotirzepatide | Eli Lilly | Type 2 diabetes, ages 10 and up, and lowering heart risk in adults with type 2 diabetes at high risk. Not weight loss: that use is off-label | A weekly pen | 2.5 to 15 mg | $499 at LillyDirect, every dose | With type 2 diabetes, your plan or Part D may cover it. Not on the Bridge |
| Wegovy pensemaglutide | Novo Nordisk | Weight loss (adults, and children 12 and up with obesity); lowering heart risk with heart disease; MASH, a liver disease, in adults | A weekly pen | 0.25 to 2.4 mg; Wegovy HD 7.2 mg | $349 at NovoCare ($399 for HD); $199 for a new patient’s first two fills through December 31, 2026 | Bridge: $50 if you qualify. Savings card: as little as $25 with coverage |
| Wegovy pillsemaglutide | Novo Nordisk | Weight loss, and lowering heart risk with heart disease, in adults | A daily pill, on an empty stomach | 1.5 to 25 mg | $149 (1.5 mg), $199 (4 mg), $299 (9 or 25 mg) at NovoCare | Bridge: $50 if you qualify |
| Foundayoorforglipron | Eli Lilly | Weight loss in adults with obesity, or overweight with a weight-related problem | A daily pill, any time, with or without food | 0.8 to 17.2 mg | $149 (0.8 or 2.5 mg), $199 (5.5 mg), $299 (9 to 17.2 mg) at LillyDirect | Bridge: $50 if you qualify. The 2.5 and 5.5 mg prices are reduced through December 31, 2026 |
| Compounded tirzepatidenot Zepbound | A state-licensed pharmacy, for one patient’s prescription | Not FDA-approved | Usually a weekly shot from a vial | Set by your provider | $139 to $399 online in our price index (median $237, 14 programs). At NexLife: $139 on the 12-month plan, $169 month to month | Not on the Bridge |
Swipe the table sideways to see every column.
Self-pay prices from LillyDirect, NovoCare and wegovy.com, checked November 1, 2026, for the medication alone. Compounded prices are all in, month to month, from our
Not compared here: liraglutide (Saxenda), and non-
How well does each work? Trial results, side by side, are on our tirzepatide vs. semaglutide guide. This page sticks to price, access and coverage.
The NexLife Price Match Guarantee†
Keep your price.
Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Which fits you
Which Zepbound alternative fits your situation?
Start with why you’re looking. Each pick comes with its catch, and your provider decides which medicine and dose are right for you. Prices checked November 1, 2026.
| Best for | Option | Price | The catch |
|---|---|---|---|
| One price at every dose, with care included | Compounded tirzepatide at NexLife (publisher of this guide) | $139 a month on the 12-month plan; $169 month to month | Not Zepbound and not FDA-approved: a licensed provider prescribes it only when it offers a significant difference for you. The $139 needs the 12-month plan. |
| Staying on Zepbound, paying yourself | Zepbound at LillyDirect | $299 at 2.5 mg, $399 at 5 mg; $449 from 7.5 mg with a refill within 45 days, or $499 to $699 | The medication alone: needles are extra, and Lilly can change or end its 45-day program at any time. |
| A lower self-pay price at most doses | Wegovy pen, from NovoCare | $349 a month ($399 for HD 7.2 mg); $199 for a new patient’s first two fills through December 31, 2026 | A different medicine, semaglutide: it takes a new prescription, and there’s no official dose conversion. |
| A plan that stopped covering Zepbound | Wegovy or Foundayo, if your plan covers them | Depends on your plan | Ask for the reason in writing, and appeal if the denial is about medical need. |
| Needles are the problem | Foundayo or the Wegovy pill | $149 to $299 a month, by dose | Foundayo’s 2.5 and 5.5 mg prices are reduced only through December 31, 2026. The Wegovy pill is taken on an empty stomach. |
| Medicare Part D | The Medicare | $50 a month, if you qualify | Covers the Zepbound KwikPen, Wegovy and Foundayo, not Zepbound vials, and is set to end December 31, 2027. |
| Type 2 diabetes | Mounjaro | $499 a month at LillyDirect, every dose | Approved for type 2 diabetes, not weight loss, so using it for that is off-label. |
Every way to pay
What does each Zepbound alternative cost, every way to pay?
Without coverage, a month runs $149 to $499 for the FDA-approved options (Zepbound’s $449 needs a refill within 45 days, or it’s $499 to $699), and $139 to $399 for compounded tirzepatide. Here’s every route, with a year’s total where it helps.
| How you pay | A month | A year at that price | Good to know |
|---|---|---|---|
| Insurance that covers Zepboundwith Lilly’s savings card | As little as $25 | Depends on your plan | For the single-dose pen: up to $100 off a month and $1,300 a year. Not for government insurance. Ends December 31, 2026 |
| Zepbound at LillyDirectvials or KwikPen, self-pay | $299 to $449 by dose | $5,187 at 5 mg to $5,837 from 7.5 mg (13 fills; the $449 needs each refill within 45 days) | Refill within 45 days, or pay $499 at 7.5 mg and $699 from 10 mg. Needles are extra |
| Zepbound pen, plan won’t cover itcommercial insurance, savings card | As low as $499 | For the single-dose pen at a pharmacy. LillyDirect’s vials and KwikPen cost less. Ends December 31, 2026 | |
| TrumpRx.govZepbound vials | $299 and up | Lilly’s own starting price; Lilly fills vial orders through LillyDirect | |
| Medicare | $50 | Zepbound KwikPen, Wegovy or Foundayo, through December 31, 2027. Not vials. Doesn’t count toward your Part D out-of-pocket limit | |
| Mounjaro at LillyDirectfor type 2 diabetes | $499 every dose | Approved for type 2 diabetes, not weight loss; that use is off-label | |
| Wegovy pen at NovoCareself-pay | $349 $399 for HD 7.2 mg | $4,537 (13 fills), or $4,237 with two $199 starter fills | New patients pay $199 for each of their first two fills, through December 31, 2026 |
| Wegovy pill at NovoCare30 tablets a bottle | $149 to $299 by dose | $3,588 at $299 (12 bottles) | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 or 25 mg |
| Foundayo at LillyDirect30-day months | $149 to $299 by dose | $3,588 at $299 (12 months) | 2.5 and 5.5 mg reduced through December 31, 2026, then $199 and $299 (TrumpRx.gov). 14.5 and 17.2 mg need refills within 45 days |
| Compounded tirzepatide online14 programs; not FDA-approved | $139 to $399 median $237 | Varies by program | All in, month to month (checked November 1, 2026). Nine of the 14 say the price is the same at every dose |
| NexLifecompounded tirzepatide, 12-month plan | $139 | $1,668 | The same at every dose, no membership fee. Not FDA-approved |
| NexLifecompounded tirzepatide, month to month | $169 | $2,028 | Paying less elsewhere for compounded tirzepatide? Price Match Guarantee† |
Swipe the table sideways to see every column.
Brand-name prices from the makers and TrumpRx.gov, checked November 1, 2026, for the medication alone. A pen, KwikPen or vial fill covers 28 days, so a year is 13 fills; a pill month is 30 days. Compounded prices from our price index, checked November 1, 2026. Year totals are our arithmetic.
The gap, over a year. From 7.5 mg up, Zepbound at LillyDirect is $449 a fill with refills within 45 days ($499 to $699 if you miss one), and 13 fills make $5,837. Compounded tirzepatide at NexLife is $1,668 for a year on the 12-month plan, $4,169 less, or $2,028 month to month. It’s a different product: compounded tirzepatide isn’t FDA-approved, and it wasn’t studied in Zepbound’s trials.
Already paying less for compounded tirzepatide? If another licensed U.S. provider or clinic charges you a lower regular monthly price, our Price Match Guarantee† matches it, with a receipt from the last 60 days.
Zepbound for less
Can you stay on Zepbound and pay less?
Yes, if you pay yourself through LillyDirect: $299 to $449 a month for vials or the KwikPen; the $449 needs a refill within 45 days, or it’s $499 to $699. At a pharmacy, a plan that won’t cover it can leave the single-dose pen at $499, even with Lilly’s card.
| Price | The same for both: $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 to 15 mg, with refills within 45 days |
|---|---|
| A month’s supply | One KwikPen with four weekly doses, or four single-dose vials, for 28 days |
| Where to buy | Vials: only from LillyDirect, self-pay only. KwikPen: LillyDirect, which accepts select insurance too |
| Supplies | Pen needles for the KwikPen; needles and syringes for vials. Both are bought separately |
| Medicare’s Bridge | Covers the KwikPen only, not vials or single-dose pens |
| HSA or FSA | Lilly lists both as HSA/FSA eligible; eligibility may vary by plan |
| The 45-day rule | Lilly’s Self Pay Journey Program, running since February 23, 2026, keeps 7.5 mg and up at $449. Miss the window, and 7.5 mg is $499 and 10 mg or more $699. Lilly can change or end the program at any time |
Two label points before you change forms. 2.5 mg is a starting dose, not a maintenance dose. And never share a KwikPen with anyone, even with a new needle.
TrumpRx.gov lists Zepbound vials starting at $299, and Lilly fills those orders through LillyDirect. Lilly’s savings cards, including its KwikPen self-pay card, end December 31, 2026; LillyDirect’s own prices list no end date. Every dose and a first year’s total: Zepbound cost without insurance.
Mounjaro
Is Mounjaro an alternative to Zepbound?
Only if you have type 2 diabetes. Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, but Mounjaro is approved for type 2 diabetes, not weight loss, so using it for weight loss alone is off-label.
Its approved use. Mounjaro helps lower blood sugar in people with type 2 diabetes aged 10 and up, and lowers the risk of heart attack, stroke or heart-related death in adults with type 2 diabetes at high risk, Lilly says. A plan may deny it for weight loss alone.
The price. At LillyDirect, Mounjaro is $499 a month at every dose, more than Zepbound at any dose with refills within 45 days ($299 to $449; otherwise $499 to $699). Without diabetes coverage, it isn’t a cheaper way to get tirzepatide.
With type 2 diabetes, your plan or Medicare Part D may cover it. People with type 2 diabetes aren’t eligible for Medicare’s
Wegovy
Is Wegovy a cheaper alternative to Zepbound?
At most doses, yes: Wegovy pens are $349 a month self-pay, against $449 for Zepbound from 7.5 mg with refills within 45 days ($499 to $699 if not), and the Wegovy pill is $149 to $299.
A different medicine. Wegovy is semaglutide, which acts on
The prices. New NovoCare patients pay $199 for each of their first two fills, through December 31, 2026; then $349, or $399 for Wegovy HD 7.2 mg. With commercial coverage of Wegovy, Novo’s savings card can bring it to as little as $25 a month; it isn’t for government insurance.
If your plan prefers Wegovy, a switch may cost a copay instead of a self-pay price. CVS Caremark’s template formularies took Zepbound back on October 1, 2026, as an additional preferred option, and each plan sponsor can still customize coverage (CVS Health, May 28, 2026).
Also approved: Wegovy lowers the risk of heart attack, stroke and heart-related death in adults with heart disease and overweight or obesity, and the pen treats MASH, a liver disease, in some adults (Wegovy label, June 2026).
Pills
Is there a pill alternative to Zepbound?
Yes. Foundayo and the Wegovy pill are once-daily
| Foundayo | Wegovy pill | |
|---|---|---|
| Approved for | Weight loss in adults with obesity, or overweight with a weight-related problem (approved April 1, 2026) | Weight loss, and lowering heart risk in adults with heart disease |
| How you take it | Once a day, any time, with or without food or water | Once a day in the morning on an empty stomach, with up to 4 ounces of water; then wait at least 30 minutes to eat, drink or take other pills |
| Self-pay, a month | $149 at 0.8 or 2.5 mg, $199 at 5.5 mg, $299 at 9 to 17.2 mg (LillyDirect) | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 or 25 mg (NovoCare) |
| Watch the dates | The 2.5 and 5.5 mg prices are reduced through December 31, 2026; TrumpRx.gov lists their regular prices as $199 and $299 | No end date listed for the pill’s prices |
Swipe the table sideways to see every column.
From Lilly’s approval release, LillyDirect, TrumpRx.gov, NovoCare and the Wegovy label, checked November 1, 2026.
On Medicare Part D? The Bridge covers both pills at $50 a month if you qualify.
Pill or weekly shot? A pill skips the needle; a shot is one dose a week. More on choosing:
Compounded
Is compounded tirzepatide an alternative to Zepbound?
It can be, when a licensed provider decides it offers a significant difference for you. It isn’t Zepbound: it isn’t FDA-approved, and it wasn’t studied in Zepbound’s trials.
- Who makes it: a state-licensed pharmacy prepares it for one patient’s prescription. NexLife’s partner pharmacies are Absolute Pharmacy (Lutz, FL) and Boudreaux’s New Drug Store (Lake Charles, LA).
- What it costs: $139 to $399 a month online, all in, across the 14 programs in our price index (median $237, checked November 1, 2026). Nine of the 14 say the price is the same at every dose. The lowest month to month is PreventiveMD’s $139; at NexLife, it’s $139 a month on the 12-month plan or $169 month to month. Paying less elsewhere? Price Match Guarantee†.
- What to check: the all-in price in month two, whether the price climbs with your dose, and which pharmacy fills your prescription.
- What the FDA advises: get a prescription and fill it at a state-licensed pharmacy, and be wary of a seller that “offers medicine at deep discounts or prices that seem too good to be true” (FDA, October 1, 2026).
Side by side: compounded vs. brand-name tirzepatide. What it is: compounded tirzepatide, explained.
Side by side
Zepbound or compounded tirzepatide at NexLife?
The same questions for both, from the facts on this page. They’re different products: compounded tirzepatide isn’t Zepbound and isn’t FDA-approved. Prices checked November 1, 2026.
| Zepbound at LillyDirect | Compounded tirzepatide at NexLife | |
|---|---|---|
| Price | $299 at 2.5 mg, $399 at 5 mg; $449 from 7.5 mg with a refill within 45 days, or $499 to $699 | $139 a month on the 12-month plan; $149 (6-month), $159 (3-month) or $169 month to month |
| Same price at every dose? | No: it rises with your dose | Yes, from 2.5 mg to 15 mg |
| What the price covers | The medication alone; needles and syringes are bought separately | The medication, your licensed provider, a nutrition plan, a 1:1 coaching call and free expedited shipping, with no membership fee |
| Plan and canceling | One 28-day fill at a time. Lilly can change or end its 45-day program at any time | Plans renew until you cancel. Cancel by email, effective 30 days after we receive it |
| Who fills it | LillyDirect: vials only there, self-pay; the KwikPen there too | Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA), state-licensed 503A pharmacies |
| FDA status | FDA-approved for weight loss and keeping it off, and for moderate to severe sleep apnea with obesity, in adults | Not FDA-approved, and not studied in Zepbound’s trials. A provider prescribes it only when it offers a significant difference for you |
| Medicare’s $50 Bridge | Covers the KwikPen if you qualify, not vials | Not covered |
Zepbound prices from LillyDirect; NexLife’s from its plans page; the Bridge from Medicare.gov. Moving from Zepbound? See Zepbound to compounded tirzepatide.
Denied?
What if your insurance denies Zepbound?
Find out why first. A denial about medical need can be appealed; a plan that excludes weight-loss drugs made a benefits decision, so look at the covered routes instead.
Ask for the reason in writing
It tells you what to do next: meet a prior authorization rule, try the brand your plan prefers, or pay another way.
Look for a covered route
Your plan may cover Wegovy or Foundayo instead. With moderate to severe sleep apnea and obesity, ask whether Zepbound is covered for that use: it’s one of its approved ones.
Appeal with your prescriber
A letter can give your starting BMI, weight-related conditions and what you’ve tried. Zepbound’s label covers keeping weight off long term, which helps if a renewal was denied after you lost weight.
Keep to the deadlines
Appeals and external reviews run on set timelines. The steps, with each deadline: insurance dropped your Zepbound or Wegovy?
Exclusions are spreading. In Mercer’s survey of large employers, 6% dropped
What’s changing
What changes for Zepbound and its alternatives in 2027?
Several offers end on December 31, 2026, and Medicare’s Bridge runs through 2027. Each date below comes from the maker, the plan or Medicare.
CVS Caremark’s template formularies add Zepbound back as an additional preferred option. Plan sponsors can still customize coverage.
Lilly’s Zepbound savings cards end, their terms say, including the KwikPen self-pay card. LillyDirect lists no end date for its own self-pay prices.
Wegovy’s $199 price for a new patient’s first two pen fills ends. At NovoCare, the prescription must be written and received by then, and ship by January 31, 2027.
Foundayo’s reduced 2.5 and 5.5 mg prices end. TrumpRx.gov lists their regular prices as $199 and $299.
Wegovy’s list price falls to $675. Novo Nordisk says the change doesn’t affect its self-pay prices.
Medicare’s
GLP-1 Bridge is set to end; its prior authorizations last through this date.
Who qualifies for the Bridge? Adults 18 and up with Part D who, when they start
Employer plans in 2027:
Safety
What should you know about safety before you switch?
Every option here is a prescription medicine with real risks, and your provider goes through them with you. These facts come from Zepbound’s label, revised August 2026.
- Boxed warning. In rats, tirzepatide caused thyroid C-cell tumors; whether it does in people isn’t known. Don’t use it if you or a family member has had medullary thyroid carcinoma (MTC), or if you have MEN 2.
- Also don’t use it if you’ve had a serious allergic reaction to tirzepatide or anything in the product.
- Common side effects: nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection-site reactions, tiredness, allergic reactions, burping, hair loss and reflux.
- Serious risks the label lists: severe stomach problems, kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions, low blood sugar with insulin or medicines that raise insulin, such as sulfonylureas, and worsening diabetic eye disease in type 2 diabetes.
- When to act: stop it and call your provider if pancreatitis is suspected, get help right away for signs of a serious allergic reaction, and tell your care team before any surgery with anesthesia or deep sedation.
- Birth control pills may work less well: switch to a non-oral method, or add a barrier method, for 4 weeks after you start and for 4 weeks after each dose increase.
- Pregnancy: stop Zepbound when a pregnancy is recognized. Weight loss offers no benefit in pregnancy and may harm the baby, the label says.
- Switching: the label doesn’t recommend using tirzepatide with another
GLP-1 medicine, so your provider times the change.
Wegovy and the Wegovy pill carry a thyroid boxed warning too, and Wegovy’s label says to stop it at least 2 months before a planned pregnancy. Questions about a side effect? Call or text us 24/7 at
At NexLife
Compounded tirzepatide at NexLife: what you get
One monthly price at every dose, with your care included. A licensed provider decides if it’s right for you.
| 12-month plan | $139 a month |
|---|---|
| 6-month plan | $149 a month |
| 3-month plan | $159 a month |
| Month to month | $169 a month |
One price at every dose
From 2.5 mg to 15 mg, with no membership fee. Your dose goes up; your price doesn’t.
A licensed provider decides
They review your health history and the dose you’re on now, online or by secure video where your state requires a live visit.
Two named pharmacies
Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA), state-licensed 503A pharmacies, prepare your prescription.
Shipping and support
Free expedited shipping, usually within 1 to 2 business days, plus a nutrition plan and a 1:1 coaching call.
Ways to pay
Card, HSA or FSA, with a letter of medical necessity if your plan asks for one, or Affirm, Klarna or Afterpay at checkout.
Real people, 24/7
Call or text
(949) 818-8000 . We follow up with the pharmacy for you.
Switching from another compounded program? Our Price Match Guarantee† matches a lower regular monthly price from another licensed U.S. telehealth provider or clinic, with a receipt from the last 60 days. It isn’t open to people with Medicare, Medicaid or TRICARE.
On Medicare? You can still pay for yourself at NexLife. If you qualify for the Bridge, its $50 a month costs less.
Who’s behind it. Our medical director is Adam Kennah, MD, board-certified in emergency medicine (American Board of Emergency Medicine). NexLife is LegitScript-certified and rated 4.8 out of 5 on Trustpilot from 407 reviews (read November 1, 2026). Not prescribed? You aren’t charged for medication.
Two medications.
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $139/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication
12-month plan $119/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
Zepbound alternatives: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
What are the alternatives to Zepbound?
If Zepbound costs too much, the main options are Wegovy pens at $349 a month, Foundayo or the Wegovy pill at $149 to $299, and Mounjaro only with type 2 diabetes (checked November 1, 2026). In our index, compounded tirzepatide is $139 to $399 month to month; it isn’t FDA-approved, and a licensed provider decides if it fits you.
What is the cheapest alternative to Zepbound?
With Medicare Part D, the
Is Mounjaro a cheaper alternative to Zepbound?
No, if you refill Zepbound on time. At LillyDirect, Mounjaro is $499 a month at every dose, while Zepbound is $299 to $449; its $449 needs a refill within 45 days, or it’s $499 to $699 (checked November 1, 2026). Mounjaro is approved for type 2 diabetes, not weight loss, so using it for weight loss is off-label.
Does switching from Zepbound to Wegovy save money?
From 5 mg of Zepbound up, yes: Wegovy pens are $349 a month self-pay, or $199 for a new patient’s first two fills through December 31, 2026. Zepbound is $399 at 5 mg and $449 from 7.5 mg; the $449 needs a refill within 45 days, or it’s $499 to $699. Wegovy is semaglutide, a different medicine.
Is there a pill alternative to Zepbound?
Yes. Foundayo (orforglipron) and the Wegovy pill are once-daily
Can compounded tirzepatide replace Zepbound?
Only if a licensed provider decides it offers a significant difference for you. It isn’t Zepbound: a state-licensed pharmacy prepares it for one patient, it isn’t FDA-approved, and it wasn’t studied in Zepbound’s trials. It costs $139 to $399 a month in our price index (November 1, 2026); at NexLife, $139 on the 12-month plan or $169 month to month.
Which Zepbound alternatives might my insurance still cover?
Ask about Wegovy and Foundayo if your plan prefers them, Mounjaro if you have type 2 diabetes, and Zepbound itself for moderate to severe sleep apnea with obesity, an approved use. CVS Caremark’s template formularies added Zepbound back on October 1, 2026, though each plan can customize its coverage.
Does Medicare’s GLP-1 Bridge cover Zepbound alternatives?
It covers Wegovy, Foundayo and Zepbound’s KwikPen for $50 a month through December 31, 2027, if you have Part D and meet its BMI and health criteria. It excludes people with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease, and doesn’t cover Zepbound vials, Mounjaro or compounded tirzepatide (Medicare.gov, checked November 1, 2026).
Will Zepbound alternatives cost more in 2027?
Some offers end first: Lilly’s savings cards, Novo’s $199 price for a new patient’s first two Wegovy fills and Foundayo’s reduced 2.5 and 5.5 mg prices all end December 31, 2026. LillyDirect lists no end date for Zepbound’s self-pay prices, and Novo says Wegovy’s lower 2027 list price doesn’t change its self-pay prices.
Is a generic alternative to Zepbound available?
No. As of November 1, 2026, the FDA hasn’t approved any generic tirzepatide, and Lilly lists its U.S. compound patent through 2036, as our generic tirzepatide guide explains. Compounded tirzepatide isn’t a generic: the FDA says compounded drugs aren’t FDA-approved.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and checked this page
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Makers’ prices, Medicare’s rules and the labels checked November 1, 2026; compounded prices November 1, 2026.
- How we checked. Every price comes from the maker’s own pages, read on November 1, 2026: LillyDirect for Zepbound, Mounjaro and Foundayo, Lilly’s savings and program terms, wegovy.com and NovoCare for Wegovy, and TrumpRx.gov. Medicare’s rules come from Medicare.gov and CMS, coverage changes from CVS Health and Mercer, and safety facts from the Zepbound and Wegovy labels, read the same day. Compounded prices come from our
GLP-1 price index, checked November 1, 2026. A year’s total is our arithmetic from those prices, and we don’t forecast prices. Zepbound, Mounjaro and Foundayo are trademarks of Eli Lilly and Company; Wegovy, Saxenda, Ozempic and Rybelsus of Novo Nordisk. NexLife isn’t affiliated with either. - Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
Paying less elsewhere? We match it.†
You know the alternatives. Next: a 3-minute check.
A licensed provider reviews your health history and decides if compounded tirzepatide is right for you: $139 a month on the 12-month plan, or $169 month to month, at every dose.
4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, or by secure video where your state requires a live visit. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- LillyDirect: Zepbound self-pay prices, KwikPen and vials (CMAT-05333 08/2026). Checked November 1, 2026.
- Eli Lilly: Zepbound full terms and conditions (Self Pay Journey Program and savings cards). Read November 1, 2026.
- Eli Lilly: Zepbound savings card and coverage. Read November 1, 2026.
- LillyDirect: Mounjaro self-pay prices. Checked November 1, 2026.
- LillyDirect: Foundayo self-pay prices. Checked November 1, 2026.
- Eli Lilly: FDA approves Foundayo (orforglipron) (April 1, 2026). Read November 1, 2026.
- Novo Nordisk: What to pay for Wegovy. Checked November 1, 2026.
- NovoCare Pharmacy: self-pay terms and prices. Read November 1, 2026.
- TrumpRx.gov: Zepbound vial. Checked November 1, 2026.
- TrumpRx.gov: Wegovy pen. Checked November 1, 2026.
- TrumpRx.gov: Foundayo. Checked November 1, 2026.
- Medicare.gov: Weight loss drugs (the Medicare
GLP-1 Bridge). Read November 1, 2026. - CMS: Medicare
GLP-1 Bridge (page modified July 13, 2026). Read November 1, 2026. - CVS Health: CVS Caremark delivers affordability and access to
GLP-1 weight management medications with expanded coverage options (May 28, 2026). Read November 1, 2026. - Mercer: Employers are shifting healthcare costs to employees, survey on health and benefit strategies for 2027 (June 11, 2026). Read November 1, 2026.
- Zepbound (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 1, 2026.
- Wegovy (semaglutide) prescribing information, Novo Nordisk, revised June 2026. Read November 1, 2026.
- FDA: Compounding and the FDA, questions and answers. Read November 1, 2026.
- FDA: Concerns with unapproved
GLP-1 drugs used for weight loss (updated October 1, 2026). Read November 1, 2026. - Novo Nordisk: US list price reduction for Wegovy, Ozempic and Rybelsus (February 24, 2026). Read November 1, 2026 for our Wegovy 2027 price guide.
- NexLife:
GLP-1 price index. Compounded prices checked November 1, 2026. - NexLife: generic tirzepatide, where it stands. Checked November 1, 2026.
- NexLife: pricing, every plan.
- NexLife on Trustpilot. 4.8 out of 5 from 407 reviews, read November 1, 2026.